Global Adeno-Associated Virus (AAV) Vector-Based Gene TherapyMarket
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is estimated to be worth over USD21.2 Bn in 2033 and is expected to grow at CAGR of 15.1% during the forecast period (2024-2033).
The global adeno-associated virus (AAV) vector-based gene therapy market is experiencingsignificant growth and evolution fueled by a combination of factors. Central to this growth is the elevating prevalence of genetic disorders and chronic illnesses, requiring novel therapeutic approaches. AAV-based gene therapy, with its ability to offer therapeutic genes into target cells with efficiencyand precision, has surfaced as a favourable solution to address these unmet medical needs. Significant developments in the market comprise the expansion of therapeutic applications beyond rare genetic disorders to embodies a comprehensive range of diseases. Neurodegenerative disorders, cardiovascular diseases, and various kinds of cancer are now among the target areas for AAV-based gene therapies, underlining the versatility and potential impact of this technology.
Advancements in capsid engineering techniques have been crucial in encouraging innovation within the market. By modifying the outer protein shell of AAV vectors, researchers can improve tissue specificity, enhance transduction efficiency, and mitigate immunogenicity. These enhancements not only diversify the therapeutic applicability of AAV-based gene therapies but also improve their safety and efficacy profiles. Furthermore, there is a soaring interest in diversifying delivery modalities for AAV vectors. Alternative routes such as intrathecal administration and direct tissue injection are being explored to optimize therapeutic outcomes and expand the scope of treatable diseases.
The market is marked by growing investment and collaboration across industry sectors, comprising pharmaceutical firms, biotechnology companies, and academic institutions. These partnerships accelerate innovation, propel research, and support the translation of scientific discoveries into clinical applications. With regulatory approvals for AAV-based gene therapies on the surge and a strong pipeline of candidates in various stages of development, the global AAV vector-based gene therapy market is poised for continued expansion. This growth offers transformative treatment options for patients worldwide, marking a substantial milestone in the domain of gene therapy and paving the way for improved outcomes in the management of genetic disorders and chronic diseases.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket and its likely evolution in the mid-to-long term.
A brief introduction to the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
A detailed assessment of the market landscape of Adeno-Associated Virus (AAV) Vector-Based Gene Therapythat are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Gene Therapy Application (Neurological Disorders, Ophthalmic Diseases, Muscular Disorders, Hematological Disorders), By Adeno-Associated Virus Serotype (AAV1, AAV2, AAV5, AAV9), By End-User (Hospitals, Research Institutes, Biopharmaceutical Companies), By Therapeutic Area (Rare Diseases, Oncology, Cardiovascular Diseases, Genetic Disorders), By Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various Adeno-Associated Virus (AAV) Vector-Based Gene Therapydevelopers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various Adeno-Associated Virus (AAV) Vector-Based Gene Therapyfocused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapyover the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Gene Therapy Application (Neurological Disorders, Ophthalmic Diseases, Muscular Disorders, Hematological Disorders), By Adeno-Associated Virus Serotype (AAV1, AAV2, AAV5, AAV9), By End-User (Hospitals, Research Institutes, Biopharmaceutical Companies), By Therapeutic Area (Rare Diseases, Oncology, Cardiovascular Diseases, Genetic Disorders), By Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.